Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.

Clinical & experimental ophthalmology·2026

Same author

Non-Arteritic Anterior Ischaemic Optic Neuropathy and Its Masquerades: A Comprehensive Diagnostic Review.

Clinical & experimental ophthalmology·2026

Same author

More Than Meets the Eye: A Case of Delayed Sequential Bilateral Vision Loss.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025

Same author

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Neurology·2025

Same author

Neuroretinitis: a comprehensive review on aetiologies, clinical manifestations, and treatment options.

Eye (London, England)·2024

Same author

Herpes Zoster Ophthalmicus Uveitis: Onset and Complications.

American journal of ophthalmology·2024

Same journal

Trends in pediatric uveitis: A systematic review and meta-epidemiological investigation of geographic, economic, and climate factors.

Survey of ophthalmology·2026

Same journal

Efficacy and safety of different intraocular therapies for non-infectious uveitis: A network meta-analysis.

Survey of ophthalmology·2026

Same journal

Macular telangiectasia masqueraders.

Survey of ophthalmology·2026

Same journal

Utilization of anterior segment optical coherence tomography in childhood glaucoma: A systematic review.

Survey of ophthalmology·2026

Same journal

Peripapillary pachychoroid syndrome: Clinical and imaging features, diagnostic differentiation and therapeutic strategies.

Survey of ophthalmology·2026

Same journal

Prognostic factors and postoperative outcomes in pediatric cataract patients: A systematic review and meta-analysis.

Survey of ophthalmology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 27, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

New developments in giant cell arteritis.

Larry Frohman¹, Aaron B C Wong², Kaliopy Matheos²

¹Department of Ophthalmology, Rutgers-New Jersey Medical School, New Jersey, USA; Department of Neurosciences, Rutgers-New Jersey Medical School, New Jersey, USA.

Survey of Ophthalmology

|January 18, 2016

Summary

This summary is machine-generated.

Giant cell arteritis (GCA) diagnosis and treatment are evolving. Temporal artery biopsy remains key, but new imaging and therapies like IL-6 inhibitors show promise for this large vessel vasculitis.

Keywords:

corticosteroids diagnosis giant cell arteritis pathogenesis temporal arteritis therapy

More Related Videos

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

Published on: January 25, 2017

Mouse Models for Graft Arteriosclerosis

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

Related Experiment Videos

Last Updated: Mar 27, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

Development and Identification of a Novel Subpopulation of Human Neutrophil-derived Giant Phagocytes In Vitro

Published on: January 25, 2017

Mouse Models for Graft Arteriosclerosis

Mouse Models for Graft Arteriosclerosis

Published on: May 14, 2013

Area of Science:

Rheumatology
Immunology
Vascular Medicine

Background:

Giant cell arteritis (GCA) is a serious medium-to-large vessel vasculitis.
Recent advancements challenge traditional diagnostic guidelines and understanding of GCA.
The American College of Rheumatology criteria for GCA diagnosis face scrutiny.

Purpose of the Study:

To review current understanding of GCA pathogenesis, diagnosis, and treatment.
To highlight evolving diagnostic approaches and therapeutic strategies for GCA.
To discuss the relationship between GCA, Takayasu arteritis, and polymyalgia rheumatica.

Main Methods:

Review of recent literature on GCA pathogenesis, diagnosis, and treatment.
Analysis of the utility of temporal artery biopsy in current clinical practice.
Evaluation of emerging diagnostic modalities like positron emission tomography (PET).

Main Results:

Erythrocyte sedimentation rate (ESR) can be affected by medications (statins, NSAIDs) and hematocrit levels.
Temporal artery biopsy remains the gold standard for GCA diagnosis, even with shorter lengths or delayed timing post-steroids.
PET imaging reveals widespread vascular inflammation in GCA, suggesting a broader disease spectrum.

Conclusions:

GCA, Takayasu arteritis, and polymyalgia rheumatica may represent a disease spectrum rather than distinct entities.
Interleukin-6 (IL-6) inhibitors show significant promise as a novel therapeutic option for GCA.
Combined therapies involving corticosteroids and immunosuppressants are crucial for managing GCA.